Intracellular amyloid formation in muscle cells of A-transgenic Caenorhabditis elegans: Determinants and physiological role in copper detoxification

Molecular Neurodegeneration

Volumn 4, Issue 1, 2009, Pages

  Minniti, Alicia N ^a   Rebolledo, Daniela L ^a   Grez, Paula M ^a   Fadic, Ricardo ^b   Aldunate, Rebeca ^a   Volitakis, Irene ^c   Cherny, Robert A ^c   Opazo, Carlos ^d   Masters, Colin ^c   Bush, Ashley I ^c,e   Inestrosa, Nibaldo C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF CONCEPCIÓN   (Chile)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAENORHABDITIS ELEGANS;

EID: 60349131260     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-4-2     Document Type: Article

References (74)

1. Inclusion-body myositis: a myodegenerative conformational disorder associated with A, protein misfolding, and proteasome inhibition. V Askanas WK Engel, Neurology 2006 66 S39 48 16432144
2. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. CL Masters G Multhaup G Simms J Pottgiesser RN Martins K Beyreuther, Embo J 1985 4 2757 2763 4065091
3. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. V Askanas WK Engel, Curr Opin Neurol 2002 15 525 531 12351995
4. Impaired innervation of cultured human muscle overexpressing APP experimentally and genetically: relevance to inclusion-body myopathies. J McFerrin WK Engel V Askanas, Neuroreport 1998 9 3201 3205 9831451
5. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. V Askanas WK Engel, Curr Opin Rheumatol 2007 19 550 559 17917534
6. Inclusion body myositis: a view from the Caenorhabditis elegans muscle. DL Rebolledo AN Minniti PM Grez R Fadic R Kohn NC Inestrosa, Mol Neurobiol 2008 38 178 198 18773311
7. Alzheimer's disease: genes, proteins, and therapy. DJ Selkoe, Physiol Rev 2001 81 741 766 11274343
8. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A fibril formation without increasing protofibril formation. Y Hori T Hashimoto Y Wakutani K Urakami K Nakashima MM Condron S Tsubuki TC Saido DB Teplow T Iwatsubo, J Biol Chem 2007 282 4916 4923 17170111
9. Physiochemical characterization of the Alzheimer's disease-related peptides A1-42Arctic and A1-42wt. AS Johansson F Berglind-Dehlin G Karlsson K Edwards P Gellerfors L Lannfelt, Febs J 2006 273 2618 2630 16817891
10. Mixtures of wild-type and a pathogenic (E22G) form of A40 in vitro accumulate protofibrils, including amyloid pores. HA Lashuel DM Hartley BM Petre JS Wall MN Simon T Walz PT Lansbury Jr, J Mol Biol 2003 332 795 808 12972252
11. Neurotoxicity and physicochemical properties of A mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. K Murakami K Irie A Morimoto H Ohigashi M Shindo M Nagao T Shimizu T Shirasawa, J Biol Chem 2003 278 46179 46187 12944403
12. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A protofibril formation. C Nilsberth A Westlind-Danielsson CB Eckman MM Condron K Axelman C Forsell C Stenh J Luthman DB Teplow SG Younkin, Nat Neurosci 2001 4 887 893 11528419
13. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. IH Cheng JJ Palop LA Esposito N Bien-Ly F Yan L Mucke, Nat Med 2004 10 1190 1192 15502844
14. The -helical to -strand transition in the amino-terminal fragment of the amyloid -peptide modulates amyloid formation. C Soto EM Castano B Frangione NC Inestrosa, J Biol Chem 1995 270 3063 3067 7852387
15. Structure and function of amyloid in Alzheimer's disease. C Morgan M Colombres MT Nunez NC Inestrosa, Prog Neurobiol 2004 74 323 349 15649580
16. The cell biology of -amyloid precursor protein and presenilin in Alzheimer's disease. DJ Selkoe, Trends Cell Biol 1998 8 447 453 9854312
17. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. J Herms B Anliker S Heber S Ring M Fuhrmann H Kretzschmar S Sisodia U Muller, Embo J 2004 23 4106 4115 15385965
18. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. JY Lee TB Cole RD Palmiter SW Suh JY Koh, Proc Natl Acad Sci USA 2002 99 7705 7710 12032347
19. Histochemically reactive zinc in plaques of the Swedish mutant -amyloid precursor protein transgenic mice. JY Lee I Mook-Jung JY Koh, J Neurosci 1999 19 RC10 10341271
20. Copper, iron and zinc in Alzheimer's disease senile plaques. MA Lovell JD Robertson WJ Teesdale JL Campbell WR Markesbery, J Neurol Sci 1998 158 47 52 9667777
21. Rapid induction of Alzheimer A amyloid formation by zinc. AI Bush WH Pettingell G Multhaup M d Paradis JP Vonsattel JF Gusella K Beyreuther CL Masters RE Tanzi, Science 1994 265 1464 1467 8073293
22. Treatment with a copper-zinc chelator markedly and rapidly inhibits -amyloid accumulation in Alzheimer's disease transgenic mice. RA Cherny CS Atwood ME Xilinas DN Gray WD Jones CA McLean KJ Barnham I Volitakis FW Fraser Y Kim, Neuron 2001 30 665 676 11430801
23. Aqueous dissolution of Alzheimer's disease A amyloid deposits by biometal depletion. RA Cherny JT Legg CA McLean DP Fairlie X Huang CS Atwood K Beyreuther RE Tanzi CL Masters AI Bush, J Biol Chem 1999 274 23223 23228 10438495
24. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. CW Ritchie AI Bush A Mackinnon S Macfarlane M Mastwyk L MacGregor L Kiers R Cherny QX Li A Tammer, Arch Neurol 2003 60 1685 1691 14676042
25. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A production in APP23 transgenic mice. TA Bayer S Schafer A Simons A Kemmling T Kamer R Tepest A Eckert K Schussel O Eikenberg C Sturchler-Pierrat, Proc Natl Acad Sci USA 2003 100 14187 14192 14617773
26. Aggregation and disaggregation of senile plaques in Alzheimer disease. L Cruz B Urbanc SV Buldyrev R Christie T Gomez-Isla S Havlin M McNamara HE Stanley BT Hyman, Proc Natl Acad Sci USA 1997 94 7612 7616 9207140
27. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human -amyloid protein precursor. I Daigle C Li, Proc Natl Acad Sci USA 1993 90 12045 12049 8265668
28. In vivo aggregation of -amyloid peptide variants. DS Fay A Fluet CJ Johnson CD Link, J Neurochem 1998 71 1616 1625 9751195
29. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid -peptide (1-42) in a transgenic Caenorhabditis elegans model. J Drake CD Link DA Butterfield, Neurobiol Aging 2003 24 415 420 12600717
30. Interaction of intracellular amyloid peptide with chaperone proteins. V Fonte V Kapulkin A Taft A Fluet D Friedman CD Link, Proc Natl Acad Sci USA 2002 99 9439 9444 12089340
31. Direct observation of stress response in Caenorhabditis elegans using a reporter transgene. CD Link JR Cypser CJ Johnson TE Johnson, Cell Stress Chaperones 1999 4 235 242 10590837
32. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. CD Link A Taft V Kapulkin K Duke S Kim Q Fei DE Wood BG Sahagan, Neurobiol Aging 2003 24 397 413 12600716
33. Amyloid - induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. Y Wu Z Wu P Butko Y Christen MP Lambert WL Klein CD Link Y Luo, J Neurosci 2006 26 13102 13113 17167099
34. A oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. FG De Felice PT Velasco MP Lambert K Viola SJ Fernandez ST Ferreira WL Klein, J Biol Chem 2007 282 11590 11601 17308309
35. A oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. PN Lacor MC Buniel PW Furlow AS Clemente PT Velasco M Wood KL Viola WL Klein, J Neurosci 2007 27 796 807 17251419
36. Inclusion Body Myositis. S Hammans, Southampton for the Muscular Dystrophy Campaign. London 2003 http://www.muscular-dystrophy.org/information- resources/factsheets/medical-conditions-factsheets/inclusion-body.html
37. In vivo reduction of amyloid- by a mutant copper transporter. AL Phinney B Drisaldi SD Schmidt S Lugowski V Coronado Y Liang P Horne J Yang J Sekoulidis J Coomaraswamy, Proc Natl Acad Sci USA 2003 100 14193 14198 14617772
38. Dramatic aggregation of Alzheimer A by Cu(II) is induced by conditions representing physiological acidosis. CS Atwood RD Moir X Huang RC Scarpa NM Bacarra DM Romano MA Hartshorn RE Tanzi AI Bush, J Biol Chem 1998 273 12817 12826 9582309
39. Metalloenzyme-like activity of Alzheimer's disease -amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). C Opazo X Huang RA Cherny RD Moir AE Roher AR White R Cappai CL Masters RE Tanzi NC Inestrosa AI Bush, J Biol Chem 2002 277 40302 40308 12192006
40. Reporter transgenes for study of oxidant stress in Caenorhabditis elegans. CD Link CJ Johnson, Methods Enzymol 2002 353 497 505 12078522
41. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. CD Link CJ Johnson V Fonte M Paupard DH Hall S Styren CA Mathis WE Klunk, Neurobiol Aging 2001 22 217 226 11182471
42. Characterization of copper interactions with alzheimer amyloid peptides: identification of an attomolar-affinity copper binding site on amyloid 1-42. CS Atwood RC Scarpa X Huang RD Moir WD Jones DP Fairlie RE Tanzi AI Bush, J Neurochem 2000 75 1219 1233 10936205
43. Transgenic Hsp 16-Lacz Strains of the Soil Nematode Caenorhabditis elegans as Biological Monitors of Environmental Stress. E Stringham E Candido, Environmental Toxicology and Chemistry 1994 13 1211 1220
44. Longevity and heavy metal resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans. D Barsyte DA Lovejoy GJ Lithgow, Faseb J 2001 15 627 634 11259381
45. Transgenic Caenorhabditis elegans strains as biosensors. EP Candido D Jones, Trends Biotechnol 1996 14 125 129 8936433
46. Copper, -amyloid, and Alzheimer's disease: tapping a sensitive connection. AI Bush CL Masters RE Tanzi, Proc Natl Acad Sci USA 2003 100 11193 11194 14506299
47. A genetic selection for Caenorhabditis elegans synaptic transmission mutants. KG Miller A Alfonso M Nguyen JA Crowell CD Johnson JB Rand, Proc Natl Acad Sci USA 1996 93 12593 12598 8901627
48. The basement membrane components nidogen and type XVIII collagen regulate organization of neuromuscular junctions in Caenorhabditis elegans. BD Ackley SH Kang JR Crew C Suh Y Jin JM Kramer, J Neurosci 2003 23 3577 3587 12736328
49. Regulation of retrograde signaling at neuromuscular junctions by the novel C2 domain protein AEX-1. M Doi K Iwasaki, Neuron 2002 33 249 259 11804572
50. Accelerating amyloid- fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. IH Cheng K Scearce-Levie J Legleiter JJ Palop H Gerstein N Bien-Ly J Puolivali S Lesne KH Ashe PJ Muchowski L Mucke, J Biol Chem 2007 282 23818 23828 17548355
51. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A and synaptic dysfunction. S Oddo A Caccamo JD Shepherd MP Murphy TE Golde R Kayed R Metherate MP Mattson Y Akbari FM LaFerla, Neuron 2003 39 409 421 12895417
52. News. In brief: New Alzheimer's endpoints? S Aldridge, Nat Biotechnol 2008 26 482 18464762
53. Y Jin, C. elegans: A practical approach Oxford: Oxford University Press 1999
54. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. A Nunomura S Chiba CF Lippa P Cras RN Kalaria A Takeda K Honda MA Smith G Perry, Neurobiol Dis 2004 17 108 113 15350971
55. Oxidative damage is the earliest event in Alzheimer disease. A Nunomura G Perry G Aliev K Hirai A Takeda EK Balraj PK Jones H Ghanbari T Wataya S Shimohama, J Neuropathol Exp Neurol 2001 60 759 767 11487050
56. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. A Nunomura G Perry K Hirai G Aliev A Takeda S Chiba MA Smith, Ann N Y Acad Sci 1999 893 362 364 10672267
57. Neuronal oxidative stress precedes amyloid- deposition in Down syndrome. A Nunomura G Perry MA Pappolla RP Friedland K Hirai S Chiba MA Smith, J Neuropathol Exp Neurol 2000 59 1011 1017 11089579
58. Metal chelation as a potential therapy for Alzheimer's disease. MP Cuajungco KY Faget X Huang RE Tanzi AI Bush, Ann N Y Acad Sci 2000 920 292 304 11193167
59. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid- peptide. T Hayashi N Shishido K Nakayama A Nunomura MA Smith G Perry M Nakamura, Free Radic Biol Med 2007 43 1552 1559 17964426
60. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. TD Rae PJ Schmidt RA Pufahl VC Culotta TV O'Halloran, Science 1999 284 805 808 10221913
61. Metals and amyloid- in Alzheimer's disease. CJ Maynard AI Bush CL Masters R Cappai QX Li, Int J Exp Pathol 2005 86 147 159 15910549
62. Overexpression of Alzheimer's disease amyloid- opposes the age-dependent elevations of brain copper and iron. CJ Maynard R Cappai I Volitakis RA Cherny AR White K Beyreuther CL Masters AI Bush QX Li, J Biol Chem 2002 277 44670 44676 12215434
63. Uptake of 67Cu by ceruloplasmin in vitro. CA Owen Jr, Proc Soc Exp Biol Med 1975 149 681 682 238216
64. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. CM Yates J Butterworth MC Tennant A Gordon, J Neurochem 1990 55 1624 1630 2213015
65. Is there a role for copper in neurodegenerative diseases? W Cerpa L Varela-Nallar AE Reyes AN Minniti NC Inestrosa, Mol Aspects Med 2005 26 405 420 16112188
66. The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2+ neurotoxicity in vivo. WF Cerpa MI Barria MA Chacon M Suazo M Gonzalez C Opazo AI Bush NC Inestrosa, Faseb J 2004 18 1701 1703 15345692
67. A novel function of monomeric amyloid -protein serving as an antioxidant molecule against metal-induced oxidative damage. K Zou JS Gong K Yanagisawa M Michikawa, J Neurosci 2002 22 4833 4841 12077180
68. Trace amounts of copper in water induce -amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. DL Sparks BG Schreurs, Proc Natl Acad Sci USA 2003 100 11065 11069 12920183
69. Expression of human -amyloid peptide in transgenic Caenorhabditis elegans. CD Link, Proc Natl Acad Sci USA 1995 92 9368 9372 7568134
70. The genetics of Caenorhabditis elegans. S Brenner, Genetics 1974 77 71 94 4366476
71. Basic culture methods. JA Lewis JT Fleming, Methods Cell Biol 1995 48 3 29 8531730
72. Creation of low-copy integrated transgenic lines in Caenorhabditis elegans. V Praitis E Casey D Collar J Austin, Genetics 2001 157 1217 1226 11238406
73. The unc-86 gene product couples cell lineage and cell identity in C. elegans. M Finney G Ruvkun, Cell 1990 63 895 905 2257628
74. A C. elegans mutant that lives twice as long as wild type. C Kenyon J Chang E Gensch A Rudner R Tabtiang, Nature 1993 366 461 464 8247153